Health Economics›Classical Hodgkin lymphoma›Untreated early-stage favorable (ESF)

Untreated early-stage favorable (ESF)

Classical Hodgkin lymphoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
ABVD Variant #01	—	R 2 916	28d	—	—	—	—	4
AVD Variant #01	—	R 2 916	28d	—	—	—	—	—
Stanford V Variant #05 Partial	—	R 2 608	28d	—	—	—	—	1
MOPP-ABV Variant #01 Partial	—	R 862	28d	—	—	—	—	—
Observation Partial	—	—	—	—	—	—	—	1
Radiation therapy N/A - radiation Partial	—	—	49d	—	—	—	—	1

6 of 6 regimens shown